Michael Ryskin's Stock Ratings

B of A Securities Analyst

Michael Ryskin is an analyst at B of A Securities. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 07/16/2024

Overall Average Return

-7.17%

Smart Score

44.2%

Overall Average Return Percentile

23rd

Number of Ratings

24
Buy NowGet Alert
07/09/2024TEMBuy Now
Tempus AI
$40.002.5% → $41Initiates → BuyGet Alert
06/25/2024ALITBuy Now
Alight
$7.0534.75%$10 → $9.5MaintainsBuyGet Alert
01/05/2024EXAIBuy Now
Exscientia
$5.4365.75%$11 → $9DowngradeBuy → NeutralGet Alert
12/12/2023MRVIBuy Now
Maravai LifeSciences
$9.20-13.04%$10 → $8UpgradeNeutral → BuyGet Alert
08/15/2023CERTBuy Now
Certara
$16.6743.97%$27 → $24MaintainsBuyGet Alert
07/31/2023AVTRBuy Now
Avantor
$21.5311.47%$27 → $24MaintainsBuyGet Alert
06/16/2023ABCMBuy Now
Abcam
—— → $25UpgradeNeutral → BuyGet Alert
04/30/2023AVTRBuy Now
Avantor
$21.5325.41%$30 → $27MaintainsBuyGet Alert
04/27/2023ALGNBuy Now
Align Tech
$247.54-9.11%$190 → $225MaintainsUnderperformGet Alert
11/04/2022ZTSBuy Now
Zoetis
$182.70-1.48%$225 → $180MaintainsBuyGet Alert
11/03/2022MRVIBuy Now
Maravai LifeSciences
$9.2084.78%$32 → $17DowngradeBuy → NeutralGet Alert
10/17/2022ALGNBuy Now
Align Tech
$247.54-19.2%$235 → $200MaintainsUnderperformGet Alert
08/10/2022OMICBuy Now
Singular Genomics Sys
$7.62-60.63% → $90DowngradeBuy → UnderperformGet Alert
07/28/2022ALGNBuy Now
Align Tech
$247.54-5.07%$260 → $235MaintainsUnderperformGet Alert
05/05/2022IDXXBuy Now
IDEXX Laboratories
$499.52-5.91%$550 → $470DowngradeBuy → NeutralGet Alert
04/18/2022RXRXBuy Now
Recursion Pharmaceuticals
$8.28——DowngradeBuy → NeutralGet Alert
02/16/2022ZTSBuy Now
Zoetis
$182.7039.03%$258 → $254MaintainsBuyGet Alert
02/03/2022ALGNBuy Now
Align Tech
$247.54101.99%$550 → $500MaintainsUnderperformGet Alert
01/07/2022OMICBuy Now
Singular Genomics Sys
$7.62175.59% → $630UpgradeNeutral → BuyGet Alert
11/11/2021SDGRBuy Now
Schrodinger
$23.92117.39%—DowngradeBuy → NeutralGet Alert
10/27/2021ZTSBuy Now
Zoetis
$182.7023.15%$225 → $225MaintainsBuyGet Alert
07/27/2021ZTSBuy Now
Zoetis
$182.7023.15% → $225MaintainsBuyGet Alert
06/21/2021OMICBuy Now
Singular Genomics Sys
$7.62241.21% → $780Initiates → NeutralGet Alert
02/12/2020ZTSBuy Now
Zoetis
$182.70-20.63%$138 → $145MaintainsNeutralGet Alert

Recent Analyst Stock Rating News

Unveiling 8 Analyst Insights On Alight
Tempus Could Gain Share In AI Health Care Market Poised To Grow By Over 30%
Tempus AI provides advanced technology to the healthcare and diagnostics market, which is expected to grow at +30%.
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Applied Therapeutics, Inc.
6 Underperforming IPO Stocks To Buy On The Dip
The U.S. IPO market was red-hot in 2021. The total number of traditional U.S. IPOs hit its highest level since the dot-com boom in the late 1990s, while total IPO deal value reached record levels last year.
Singular Genomics G4 Launch Impresses BofA Analyst: What's Next?
Singular Genomics Systems Inc (NASDAQ: OMIC) launched the G4 system in late December and has begun taking orders, with shipments expected to commence in the second quarter of 2022, according to BofA Securities.
BofA Downgrades Schrodinger On Slower Drug Discovery Ramp
Schrodinger Inc (NASDAQ: SDGR) reported downbeat third-quarter results, mainly due to lower-than-expected drug discovery revenues, according to BofA Securities.
SmileDirectClub Fails To Give Investors Any Reason To Smile
SmileDirectClub Inc’s (NASDAQ: SDC) stock plummeted after the company reported its third-quarter revenue at $137.68 million, down 18.3% year-on-year, missing the consensus estimate of $181.90 million.
Three Analysts Initiate Coverage On This AI-Based Pharmatech
BofA Upgrades Zoetis Stock On Business Potential, Valuation
Zoetis Inc (NYSE: ZTS) seems well-positioned in 2021 with the stock valuation offering an attractive entry point, according to BofA Securities.
BofA Downgrades Align Technology On Near-Term Risks Ahead Of Q2 Print
Align Technology, Inc. (NASDAQ: ALGN), a maker of orthodontic products to fix crooked teeth and other issues, has seen a stock gain of more than 130% since March and has "gotten ahead of itself," according to BofA Securities.
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free